BREO ELLIPTA (Umeclidinium) is a prescription that contains a combination of medications and is prescribed to treat asthma and chronic obstructive pulmonary disease (COPD). Asthma and COPD are diseases of the lungs that make it difficult for a person to breathe. BREO ELLIPTA is a daily medication that helps to reduce some of the symptoms like shortness of breath, coughing, and wheezing.

Breo Ellipta (Fluticasone Furoate & Vilanterol Trifenatate)

The usual dosage is one inhalation once daily when using BREO ELLIPTA for cough and the reduction of other symptoms. After inhalation, rinse the mouth with water and do not swallow. If the mouth is not rinsed after use, the risk of oropharyngeal candidiasis (oral thrush) may increase. BREO ELLIPTA should be taken every day. It is not a rescue medication and should not be used for the relief of acute bronchospasm. In the case of acute symptoms like shortness of breath, an inhaled medication like albuterol should be used for relief instead of a maintenance inhaler like BREO ELLIPTA. If used regularly, BREO ELLIPTA will reduce the severity of asthma and COPD symptoms and reduce the need for a rescue inhaler. Fact Table Formula C51H62Cl2F3NO11S License EU EMA Bioavailability 15.2% Legal status US: RX Only Chemical Name Fluticasone Furoate & Vilanterol Trifenatate Elimination half-life 24 hours Dosage (Strength) 184/22mcg(200/25mcg) (30 doses/inhaler), 92/22mcg(100/25mcg) (30 doses/inhaler)30 days 100-25mcg 30 (1 inhaler), INST 14days 100-25mcg 28 (1 inhaler) Pregnancy Consult a doctor Brands Breo Ellipta Protein binding 93% PubChem CID 71306415 MedlinePlus a603017 ChEBI 75043 ATC code R03AK10 DrugBank DB08906, DB09082 KEGG D10501 Routes of administration Inhaled
Fluticasone furoate Fluticasone is an inhaled corticosteroid medication (ICS). Corticosteroids are signaling molecules that reduce inflammation. During bronchospasms, the airways of the lungs are often swollen and inflamed, and regular usage of an ICS decreases this. Vilanterol Vilanterol is a long-acting beta2-agonist (LABA). Beta receptors are present on the surface of muscle cells in the lungs. By activating these receptors, vilanterol relaxes the muscles of the airway, making it easier to breathe.
The usage of BREO ELLIPTA may increase the risk of pneumonia and other bronchial infections in certain patients. BREO ELLIPTA may rarely cause a paradoxical reaction where the airways spasm, making it harder to breathe. If this happens while taking BREO ELLIPTA, stop the medication and tell your physician. BREO ELLIPTA should be used with caution in patients with a history of cardiovascular disorders. BREO ELLIPTA should be used with caution in diabetic patients or those with a history of hypokalemia. Speak with your physician for a full list of warnings and precautions.
Common adverse effects of BREO ELLIPTA include: Arthralgia, Back pain, Bronchitis, Cough, Dysphonia, Headache, Hypertension, Influenza, Nasopharyngitis, Oral candidiasis, Oropharyngeal pain, Pharyngitis, Pneumonia, Pyrexia, Sinusitis, Upper respiratory tract infection Breo Ellipta [package insert].Research Triangle Park, NC: GlaxoSmithKline, 2019 Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy.Read More....

Breo Ellipta (Fluticasone Furoate & Vilanterol Trifenatate)

Directions

Ingredients

Cautions

Side Effects